Open AccessTargeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC
Author(s) -
Lankes Katharina,
Hassan Zonera,
Doffo María Josefina,
Schneeweis Christian,
Lier Svenja,
Öllinger Rupert,
Rad Roland,
Krämer Oliver H.,
Keller Ulrich,
Saur Dieter,
Reichert Maximilian,
Schneider Günter,
Wirth Matthias
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12835
Subject(s) - druggability , bortezomib , cancer research , oncogene , proteasome , transcriptome , biology , pancreatic cancer , ubiquitin , synthetic lethality , proteasome inhibitor , cancer , computational biology , bioinformatics , gene , cell cycle , gene expression , immunology , genetics , multiple myeloma , dna repair
Pancreatic ductal adenocarcinoma (PDAC) cells, harboring hyperactive myelocytomatosis oncogene, are prone to unfolded protein response‐associated cell death. Perturbation of protein homeostasis by targeting the ubiquitin–proteasome system lowers the threshold to cancer cell death and may be a novel concept for the development of alternative treatment options for PDAC.